Prostate Cancer Chief Editor
E. David Crawford, MD
E. David Crawford is the distinguished Professor of Surgery, Urology, and Radiation Oncology, the Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus, Chairman of the Prostate Conditions Education Council and founder of Bingham International Center for the 3D Diagnosis and Treatment of Prostate Cancer. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles. Dr. Crawford is an internationally-recognized expert in benign prostate hypertrophy, urologic cancers, and, in particular, prostate cancer. The recipient of more than 69 research grants, he has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored more than 450 articles in such journals as Urology, The New England Journal of Medicine, the Journal of Urology and the Journal of the National Cancer Institute. He has published five textbooks and authored more than 50 book chapters, and is an editorial reviewer or consultant for Urology, Journal of Urology, The New England Journal of Medicine, Cancer and the Journal of Clinical Oncology. Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, American Urological Association (AUA) and the American Association for the Advancement of Science. Dr. Crawfords involvement in the national prostate cancer arena has been widely recognized and he has received many honors and awards, including a Freddie Award at the AMA International Health and Medical Film Competition for the program ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating). He has been recognized as one of the Best Doctors in America, one of the Best Cancer Doctors, one of the Top 20 Urologists in the Country and was selected as the Best Healthcare Provider in the Denver Metro region.
Prostate Cancer Editorial Board
Charles L. Bennett, M.D., Ph.D., M.P.P.
Charles L. Bennett, M.D., Ph.D., M.P.P., is a hematologist and oncologist whose research focuses on preventing adverse drug events and improving drug safety. An international expert in his field, Bennett was recruited in Spring 2010 as the new endowed chair of the South Carolina Center for Economic Excellence (CoEE) in Medication Safety and Efficacy and the Josie P and Frank M Fletcher Professor of Pharmacy at the University of South Carolina (USC) campus of the South Carolina College of Pharmacy. The Medication Safety and Efficacy program which Bennett leads works to prevent adverse drug effects (ADEs) and to improve drug safety. The Center was created in 2005 to study the effects of prescription and over-the-counter medications, particularly on children and the elderly. The CoEE also is focused on education and outreach to health care professionals and the general public through the Doris Levkoff Meddin Medication Safety Education Program. South Carolina is the first and only state to endow a program in pharmaceutical safety. Dr. Bennett, along with his team at the Medication Safety and Efficacy CoEE, will be developing technology that has high likelihood of commercialization, will look for ways to make drug information more consumer-friendly, and will create new training tools for health care providers.
Michael K. Brawer, MD
Michael K. Brawer, MD is Vice President Medical Affairs, Urology, Myriad Genetics Laboratories. Dr. Brawer joins Myriad from GTx inc where he served as Executive Director Medical Affairs and Clinical Development (2009-2012). Prior to this he was Chief Medical Officer, Tokai Pharmaceuticals(2007-2009) From 2006–2007, Dr. Brawer was Interim Chief Medical Officer at Threshold Pharmaceuticals. In 1998, he was a founder of the Northwest Prostate Institute, a community hospital focused on clinical practice, community outreach, basic and clinical research and medical education, and served as Director until 2007. From 1986–1998, he held various academic appointments first at the University of Arizona and then at the University of Washington where he was Professor of Urology and Adjunct Professor of Pathology. Dr. Brawer has published more than 200 scientific papers, 10 books and 74 book chapters and is the recipient of 28 peer review competitive grants. In 1998, the American Urological Association bestowed upon him the Gold Cystoscope, given annually to a urologist distinguished by outstanding contributions to the profession within 10 years of completion of residency training. Dr. Brawer received his bachelor and medical degrees from the University of California, Los Angeles, where he also completed a fellowship in pathology, and completed his residency in urology at Stanford University Medical Center, where from 1985–1986 he was Chief Resident, Urology.
Robert Dreicer, M.D., M.S., FACP, FASCO
Dr. Dreicer is Chair of the Department of Solid Tumor Oncology at the Cleveland Clinic, a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine and Deputy Associate Director for Clinical Research for the Case Comprehensive Cancer Center. Dr. Dreicer is board certified in internal medicine and medical oncology. His areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials. Dr. Dreicer received his B.S. degree at Colorado State University, his MS degree at the University of Texas Graduate School of Biomedical Sciences, and his M.D. from the University of Texas Medical School at Houston. His internal medicine residency was at Indiana University, his medical oncology fellowship at the University of Wisconsin Clinical Cancer Center in Madison, Wisconsin. He is the Co-Chair of NCI GU Steering committee and chair of the Bladder Subcommittee of ECOG. He has chaired the Department of Defense Prostate Cancer Integration Panel and the Steering Committee of ASCO’s 2008 GU Oncology meeting. He is, an Associate Editor of Urology, a member of the editorial board of New England Journal of Medicine’s Journal Watch Hematology/Oncology and a member of the ABIM Subspecialty Board on Medical Oncology.
Robert H. Getzenberg, Ph.D.
Robert H. Getzenberg, Ph.D. is the Director of Strategic Clinical Affairs at GTx Inc. Previously, he was Director of Research of the James Buchanan Brady Urological Institute and Professor of Urology at the Johns Hopkins University School of Medicine. Dr. Getzenberg received his Ph.D. from the Johns Hopkins University School of Medicine in 1992. Dr. Getzenberg then completed a post-doctoral fellowship at the Yale University School of Medicine. Dr. Getzenberg is the recipient of a number of awards including the 2000 University of Pittsburgh chancellor’s Distinguished Research Award and was selected as one of the “40 under 40” by Pittsburgh Magazine. Dr. Getzenberg has been the recipient of a number of grants from the National institutes of Health and other agencies and foundations. Dr. Getzenberg has served in a number of international leadership positions and has authored a large number of manuscripts and book chapters in the field.
Philip Kantoff, MD
Philip Kantoff, MD, is Professor of Medicine at Harvard Medical School. He is also the Chief Clinical Research Officer and Chief of the Division of Solid Tumor Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. He is the Leader of the Dana-Farber/Harvard Cancer Center Prostate Cancer Program and Director of the prostate cancer Specialized Program of Research Excellence (SPORE).
Dr. Kantoff is a clinical and translational researcher. He is the principal investigator of a laboratory whose primary focus has been on the genetics and genetic epidemiology of prostate cancer, resistance mechanisms to hormone therapy, and biomarkers relevant as potential prognostic markers and therapeutic targets. His clinical research includes clinical trials, outcomes, and laboratory-based correlative science research.
An expert in genitourinary cancers, Dr. Kantoff is the lead editor of the comprehensive text on prostate cancer, “Prostate Cancer: Principles and Practice,” published by Lippincott, Williams & Wilkins, and authored a layperson’s self-help book on prostate cancer, “Prostate Cancer: A Family Consultation,” published by Houghton Mifflin. He has also authored over 300 articles in peer-reviewed publications such as Cell , Science, Nature, JAMA, The New England Journal of Medicine and. Journal of Clinical Oncology
Dr. Kantoff graduated from Brown University Medical School in Providence, Rhode Island. After completing his internship and residency in internal medicine at New York University Hospital and Bellevue Hospital, both in New York, New York, he spent 4 years at the National Institutes of Health, Bethesda, Maryland, conducting research in gene therapy.
M. Scott Lucia, M.D.
M. Scott Lucia, M.D. is currently Professor and Vice Chair of Anatomic Pathology in the Department of Pathology. He also serves as Director of the Prostate Cancer Research Laboratories within the Department of Pathology, and as Director of the UCAMC Biorepository Core Facility. Dr. Lucia received his M.D. from the University of Colorado School of Medicine in 1988. He completed his internship and residency in pathology at the University of Colorado in 1993. He was a research fellow in the Laboratory of Chemoprevention at the National Institutes of Health from 1993-1995 before returning to Colorado in 1995. He is board-certified in anatomic and clinical pathology and subspecializes in genitourinary and renal pathology. Dr. Lucia serves on several campus committees including the UC School of Medicine Infrastructure Subcommittee of the Research Task Force and the Oncology Strategic Oversight Committee. Dr. Lucia regularly participates in the teaching of medical students as a part of the IDPT 5005 course and CHA/PA program. He has received 13 Excellence in Teaching Awards voted on by the medical students and 3 Department of Pathology Summit Awards for Excellence in Teaching and the Education of Pathologists. Dr. Lucia has also been listed in the Best Doctors in America® database since 2009.
Daniel P. Petrylak, MD
Daniel P. Petrylak, MD completed his medical degree at Case Western Reserve University School of medicine , and completed his internal medicine residency at Albert Einstein College of Medicine/Jacobi Medical center and fellowship at Memorial SloanKettering cancer center. He is currently Director of Genitourinary Oncology, and Co Director of the Signal Transduction Program at Yale University Cancer Center.
Dr. Petrylak is involved in clinical trials research on a local, national, and international level. He is the head of the advanced bladder subcommittee in the Southwest Oncology Group Genitourinary Committee. Dr. Petrylak served as PI or Co PI on 7 Southwest Oncology Group Protocols. Most notably, he served as the PI for a randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone in men with hormone refractory prostate cancer. This trial was one of two studies that demonstrated a survival benefit for docetaxel-based therapy in men with advanced prostate cancer. This trial supported the approval of docetaxel for hormone refractory prostate cancer by the FDA. He also help to design and served as principal investigator for the SPARC trial, an international registration trial evaluating the activity of satraplatin as a second line therapy for hormone refractory prostate cancer.
Dr. Petrylak is a recognized international leader in the field. He has served on the program committee for the annual meetings of the American Urological Association (2003-11) as well as for the American Society of Clinical Oncology (1995-7, 2001-3). He also has served as a committee member for the Devices and Immunolgicals section of the Food and Drug Administration. He has published extensively, in the New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, as well as Cancer Research and Clinical Cancer Research.
Kenneth J. Pienta, M.D.
Dr. Pienta has international expertise in the development of novel chemotherapeutic programs for prostate cancer. Dr. Pienta has championed the concept that translational research is often best accomplished by multi-disciplinary teams of scientists and clinicians. The success of these endeavors led to the receipt of the 2007 first annual American Association for Cancer Research Team Science Award. He is the author of more than 300 peer-reviewed articles, and been the principle investigator on numerous local and national clinical trials. Throughout his career, Dr. Pienta has effectively mentored over 40 students, residents and fellows to successful careers in medicine.
Effective March 1, 2013, Dr. Pienta will be joining the faculty of Johns Hopkins Hospital, School of Medicine as The Donald S. Coffey Professor of Urology, Director, of the Brady Urological Institute. Dr. Pienta will be leaving his current position as the Associate Vice President for Research, Health Sciences, and Director of Experimental Therapeutics for the Michigan Center for Translational Pathology.
Jack A Schalken, PhD
Jack A Schalken PhD (53) was trained as biochemist at the Radboud University Nijmegen, where he also obtained his PhD degree (1987). He did his post doc with Dr John T Isaacs at Johns Hopkins Hospital (Baltimore, MD). Since then he is director of urological research at the Radboud University Medical Center. In 1996 Dr Schalken was appointed as full professor of experimental oncology at the University of Utrecht. Since 2001 he is professor of experimental urology at the Radboud University (Nijmegen).
His research has a strong translational component, i.e. conducting life sciences research to accelerate healthcare outcomes, specific themes
- Unravelling the mechanism of GU cancer invasion/cadherin switching
- Molecular diagnostics of prostate cancer; PCA3.
- Cancer stem/initiating cells
- Targeted therapy in GU cancer
Ralph W. de Vere White, MD
Ralph W. de Vere White is associate dean for cancer programs at UC Davis School of Medicine and Medical Center. He is director of the UC Davis Comprehensive Cancer Center, and a Distinguished Professor of the Department of Urology.
Dr. de Vere White is the Director of the UC Davis Comprehensive Cancer Center and, he is the Associate Dean of Cancer Programs as well as a Distinguished Professor of Urology at the University of California, Davis. Dr. de Vere White has a proven record in leading as well as collaborating on NIH, DOD and Cooperative Group research projects. Specifically, he was the PI of the UC Davis P01 program project in prostate cancer. This group eventually evolved into the UC Davis CCSG Prostate Cancer Program (05), the only organ site of the UCD NCI funded CCSG. In addition, he was the founding PI of the UC Davis Urology Cancer Outreach Program (UCOP) as well as founder of the Genitourinary (GU) Tumor Biology Committee of the Southwest Oncology Group (SWOG).
His individual research focuus is in the area of prostate and bladder cancer, for which he has received continual NCI funding since 1985. His research is focused on the role of microRNAs (miRNAs) in prostate cancer. Dr. de Vere White has a demonstrated record of successful and productive leadership as well as a strong history of facilitating research collaborations in the area of clinical cancer research and prostate cancer.